News
A large cohort study of patients with psoriasis using wearable devices finds more exercise is associated with a lower risk ...
A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...
Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results